Kyverna Therapeutics/KYTX

$15.42

1.11%
-
1D1W1MYTD1YMAX

About Kyverna Therapeutics

Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The Company is focused on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). It intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. It is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.

Ticker

KYTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Peter Maag

Employees

100

Headquarters

Emeryville, United States

KYTX Metrics

BasicAdvanced
$658M
Market cap
-
P/E ratio
-$1.73
EPS
-
Beta
-
Dividend rate
$658M
$35.06
$12.26
391K
17.173
0.185
0.456
1.821
1.821

What the Analysts think about KYTX

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
185.34% upside
High $48.00
Low $40.00
$15.42
Current price
$44.00
Average price target

KYTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$27M
29.13%
Profit margin
0%
NaN%

KYTX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 33.33%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Actual
-$26.86
-$1.12
-
Expected
-$3.23
-$0.84
-$0.77
Surprise
732.44%
33.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Kyverna Therapeutics stock?

Kyverna Therapeutics (KYTX) has a market cap of $658M as of May 19, 2024.

What is the P/E ratio for Kyverna Therapeutics stock?

The price to earnings (P/E) ratio for Kyverna Therapeutics (KYTX) stock is 0 as of May 19, 2024.

Does Kyverna Therapeutics stock pay dividends?

No, Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders as of May 19, 2024.

When is the next Kyverna Therapeutics dividend payment date?

Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Kyverna Therapeutics?

Kyverna Therapeutics (KYTX) does not currently have a Beta indicator.

What is the Kyverna Therapeutics stock price target?

The target price for Kyverna Therapeutics (KYTX) stock is $44, which is 185.34% above the current price of $15.42. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Kyverna Therapeutics stock

Buy or sell Kyverna Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing